Senate Finance Bipartisan Duo Requests Details On Sovaldi's Price

The bipartisan duo of Senate Finance Committee Chair Ron Wyden (D-OR) and Finance member Charles Grassley (R-IA) on Friday (July 11) asked Sovaldi-manufacturer Gilead Sciences to hand over a long, detailed list of information on how the company arrived at the $84,000-per-treatment cost of the hepatitis C drug. A health care analyst said the bipartisan nature of the request indicates that Finance might hold a hearing on drug pricing, but a Democratic Finance spokesperson said nothing has been planned beyond...

Senate Finance Bipartisan Duo Requests Details On Sovaldi's Price

You've followed a link to an article or document on InsideHealthPolicy.com.There are two ways you can access this content.

Subscriber Login

Take A Trial Subscription

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.